Assessing the Benefit–risk of New Treatments Using Generalised Pairwise Comparisons: The Case of Erlotinib in Pancreatic Cancer

British Journal of Cancer- United Kingdom

doi 10.1038/bjc.2015.55

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

The Promise of Risk-Based Allocation Trials in Assessing New Treatments.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1996English

Supplemental Information 2: Differentially Expressed Transcripts From Pairwise Comparisons of Tissues or Temperature Treatments.

English

Notes on the Existence of a Solution in the Pairwise Comparisons Method Using the Heuristic Rating Estimation Approach

Annals of Mathematics and Artificial Intelligence
Applied MathematicsArtificial Intelligence
2015English

Application of the Method of Pairwise Comparisons When Combining Economic Forecasts

Accounting. Analysis. Auditing
2019English

Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor- B

Cancer Research
Cancer ResearchOncology
2006English

Automated Pancreatic Cyst Screening Using Natural Language Processing: A New Tool in the Early Detection of Pancreatic Cancer

HPB
HepatologyGastroenterology
2015English

Graded Multilabel Classification by Pairwise Comparisons

2014English

The Role of Mediterranean Diet on the Risk of Pancreatic Cancer

British Journal of Cancer
Cancer ResearchOncology
2013English

Benefit–risk Assessment of New and Emerging Treatments for Hepatitis C: Focus on Simeprevir and Sofosbuvir

Drug, Healthcare and Patient Safety
Health PolicyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy